Seasonal influenza vaccination: prioritizing children or other target groups? Part 2 : cost-effectiveness analysis

[1]  S. Esposito,et al.  Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. , 2011, Vaccine.

[2]  T. Vesikari,et al.  Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  A. Hoes,et al.  Effects of Influenza Plus Pneumococcal Conjugate Vaccination Versus Influenza Vaccination Alone in Preventing Respiratory Tract Infections in Children: A Randomized, Double-Blind, Placebo-Controlled Trial , 2008, The Journal of Pediatrics.

[4]  Georgia Salanti,et al.  Meta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines , 2011, PloS one.

[5]  John J Treanor,et al.  Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons , 2010, BMC infectious diseases.

[6]  D. Skowronski,et al.  Influenza B/Victoria Antigen Induces Strong Recall of B/Yamagata But Lower B/Victoria Response in Children Primed With Two Doses of B/Yamagata , 2011, The Pediatric infectious disease journal.

[7]  T. Tsai.  MF59 adjuvanted seasonal and pandemic influenza vaccines. , 2011, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[8]  L. Chu,et al.  Efficacy of dual vaccination of pandemic H1N1 2009 influenza and seasonal influenza on institutionalized elderly: a one-year prospective cohort study. , 2011, Vaccine.

[9]  Yan Liu,et al.  Optimal vaccination strategies for 2009 pandemic H1N1 and seasonal influenza vaccines in humans. , 2011, Vaccine.

[10]  T. Heikkinen,et al.  1165Efficacy of Live Attenuated Influenza Vaccine Upon Revaccination of Children , 2014 .

[11]  J. McCullers,et al.  Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. , 2011, Vaccine.

[12]  S. Esposito,et al.  Different influenza vaccine formulations and adjuvants for childhood influenza vaccination. , 2011, Vaccine.

[13]  D. Fleming,et al.  Cost-Effectiveness Analysis of Inhaled Zanamivir in the Treatment of Influenza A and B in High-Risk Patients , 2012, PharmacoEconomics.

[14]  M. Fakih,et al.  Effect of 25‐hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients , 2011, The Prostate.

[15]  E. Vermeire,et al.  A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. , 2011, Vaccine.

[16]  S. Esposito,et al.  Efficacy of Injectable Trivalent Virosomal-Adjuvanted Inactivated Influenza Vaccine in Preventing Acute Otitis Media in Children With Recurrent Complicated or Noncomplicated Acute Otitis Media , 2009, The Pediatric infectious disease journal.

[17]  Jean A. Roayaei,et al.  Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. , 2009, JAMA.

[18]  S. Madhi,et al.  Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  L. Shulman.  Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial , 2012 .

[20]  M. Jit,et al.  Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. , 2010, Vaccine.

[21]  M. Rothberg,et al.  Management of influenza symptoms in healthy adults , 2003, Journal of General Internal Medicine.

[22]  J. Ioannidis,et al.  Publication Delay of Randomized Trials on 2009 Influenza A (H1N1) Vaccination , 2011, PloS one.

[23]  S. Ha,et al.  Vaccines for prophylaxis of viral infections in patients with hematological malignancies. , 2011, The Cochrane database of systematic reviews.

[24]  D. Low,et al.  Respiratory illnesses in Canadian health care workers: a pilot study of influenza vaccine and oseltamivir prophylaxis during the 2007/2008 influenza season , 2011, Influenza and other respiratory viruses.

[25]  D. Blazes,et al.  Effectiveness of Seasonal Influenza Vaccines against Influenza-Associated Illnesses among US Military Personnel in 2010–11: A Case-Control Approach , 2012, PloS one.

[26]  T. Vesikari,et al.  Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. , 2009, The Journal of infectious diseases.

[27]  A. Hill,et al.  Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1 , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  E. Sacadura-Leite,et al.  Antibody response to the influenza vaccine in healthcare workers. , 2012, Vaccine.

[29]  J. Falloon,et al.  randomized , double-blind noninferiority study of quadrivalent live attenuated nfluenza vaccine in adults , 2011 .

[30]  J. Lave,et al.  Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. , 2003, JAMA.

[31]  H. Ehrlich,et al.  Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial , 2011, The Lancet.

[32]  Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1 , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  F. Villar,et al.  [Use of European Quality of Life-5 Dimensions (EQ-5D) questionnary to value the health related quality of life variation because of influenza]. , 2009, Gaceta sanitaria.

[34]  K Abrams,et al.  Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. , 2003, Health technology assessment.

[35]  T. Jefferson,et al.  Vaccines for preventing influenza in healthy children. , 2008, The Cochrane database of systematic reviews.

[36]  Nicholas S. Kelley,et al.  Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[37]  A. Monto,et al.  Comparative efficacy of inactivated and live attenuated influenza vaccines. , 2009, The New England journal of medicine.

[38]  J. Díez-Domingo,et al.  MF59™-adjuvanted seasonal influenza vaccine in young children , 2011, Expert review of vaccines.

[39]  1. Suwal,et al.  Pandemic Influenza A ( H 1 N 1 ) 2009 Outbreak Investigation in Nepal , 2011 .

[40]  Ron Goeree,et al.  Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[41]  R. Westendorp,et al.  Cytomegalovirus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. , 2011, Vaccine.

[42]  T. Heikkinen,et al.  Effectiveness and safety of influenza vaccination in children: European perspective. , 2011, Vaccine.

[43]  C. Cooper,et al.  Vitamin D Supplementation Does Not Increase Immunogenicity of Seasonal Influenza Vaccine in HIV-Infected Adults , 2011, HIV clinical trials.

[44]  D. S. Kim,et al.  Safety and Immunogenicity of a New Trivalent Inactivated Split-virus Influenza Vaccine in Healthy Korean Children: A Randomized, Double-blinded, Active-controlled, Phase III Study , 2011, Journal of Korean medical science.

[45]  R. Walker,et al.  Live attenuated influenza vaccine in children. , 2006, Seminars in pediatric infectious diseases.

[46]  J. Singer,et al.  Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults , 2011, PloS one.

[47]  Mark Jit,et al.  The Impact of Pandemic Influenza H1N1 on Health-Related Quality of Life: A Prospective Population-Based Study , 2011, PloS one.

[48]  C. Bauch,et al.  Economic Appraisal of Ontario's Universal Influenza Immunization Program: A Cost-Utility Analysis , 2010, PLoS medicine.

[49]  Y. Hirota,et al.  Inactivated influenza vaccine effectiveness against influenza-like illness among young children in Japan--with special reference to minimizing outcome misclassification. , 2009, Vaccine.

[50]  T. Vesikari,et al.  Oil-in-water emulsion adjuvant with influenza vaccine in young children. , 2011, The New England journal of medicine.

[51]  W. Blackwelder,et al.  Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine. , 2011, Vaccine.

[52]  A. Monto,et al.  Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. , 2006, The New England journal of medicine.

[53]  A. Monto,et al.  Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. , 2008, The Journal of infectious diseases.

[54]  J. Devaster,et al.  Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example , 2009, BMC infectious diseases.

[55]  Stephanie L. Dickinson,et al.  Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. , 2009, Vaccine.